Genetic correlation between amyotrophic lateral sclerosis and schizophrenia

Citation
McLaughlin, R. L., D. Schijven, W. van Rheenen, K. R. van Eijk, M. O'Brien, R. S. Kahn, R. A. Ophoff, et al. 2017. “Genetic correlation between amyotrophic lateral sclerosis and schizophrenia.” Nature Communications 8 (1): 14774. doi:10.1038/ncomms14774. http://dx.doi.org/10.1038/ncomms14774.

Published Version
doi:10.1038/ncomms14774

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:32630669

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Genetic correlation between amyotrophic lateral sclerosis and schizophrenia

Russell L. McLaughlin1,2,*, Dick Schijven3,4,*, Wouter van Rheenen3, Kristel R. van Eijk3, Margaret O’Brien1, Project MinE GWAS Consortium†, Schizophrenia Working Group of the Psychiatric Genomics Consortium‡, René S. Kahn4, Roel A. Ophoff4,5,6, An Goris7, Daniel G. Bradley2, Ammar Al-Chalabi8, Leonard H. van den Berg3, Jurjen J. Luykx3,4,9,**, Orla Hardiman2,**, & Jan H. Veldink3,**

We have previously shown higher-than-expected rates of schizophrenia in relatives of patients with amyotrophic lateral sclerosis (ALS), suggesting an aetiological relationship between the diseases. Here, we investigate the genetic relationship between ALS and schizophrenia using genome-wide association study data from over 100,000 unique individuals. Using linkage disequilibrium score regression, we estimate the genetic correlation between ALS and schizophrenia to be 14.3% (7.05–21.6; P = 1 × 10^{-4}) with schizophrenia polygenic risk scores explaining up to 0.12% of the variance in ALS (P = 8.4 × 10^{-7}). A modest increase in comorbidity of ALS and schizophrenia is expected given these findings (odds ratio 1.08–1.26) but this would require very large studies to observe epidemiologically. We identify five potential novel ALS-associated loci using conditional false discovery rate analysis. It is likely that shared neurobiological mechanisms between these two disorders will engender novel hypotheses in future preclinical and clinical studies.
Amyotrophic lateral sclerosis (ALS) is a late-onset neurodegenerative condition characterized by progressive loss of upper and lower motor neurons, leading to death from respiratory failure in 70% of patients within 3 years of symptom onset. Although ALS is often described as a primarily motor-system disease, extramotor involvement occurs in up to 50% of cases, with prominent executive and behavioural impairment, and behavioural variant frontotemporal dementia (FTD) in up to 14% of cases. A neuropsychiatric prodrome has been described in some people with ALS–FTD, and higher rates of schizophrenia and suicide have been reported in first and second degree relatives of those with ALS, particularly in kindreds associated with the C9orf72 hexanucleotide repeat expansion. These clinical and epidemiological observations suggest that ALS and schizophrenia may share heritability.

ALS and schizophrenia both have high heritability estimates (0.65 and 0.64, respectively) but the underlying genetic architectures of these heritable components appear to differ. Analysis of large genome-wide association study (GWAS) datasets has implicated over 100 independent risk loci for schizophrenia and estimated that a substantial proportion (23%) of the variance in liability for schizophrenia is due to additive polygenic risk (many risk-increasing alleles of low individual effect combining to cause disease) conferred by common genetic variants. This proportion, the single nucleotide polymorphism (SNP)-based heritability, is lower in ALS (8.2%), in which fewer than ten risk loci have been identified by GWAS. Nevertheless, both diseases have polygenic components, but the extent to which they overlap has not been investigated.

Recently, methods to investigate overlap between polygenic traits using GWAS data have been developed. These methods assess either pleiotropy (identical genetic variants influencing both traits) or genetic correlation (identical alleles influencing both traits). Genetic correlation is related to heritability; for both measures, binary traits such as ALS and schizophrenia are typically modelled as extremes of an underlying continuous scale of liability to develop the trait. If two binary traits are genetically correlated, their liabilities covary, and this covariance is determined by both traits having identical risk alleles at overlapping risk loci. Studies of pleiotropy and genetic correlation have provided insights into the overlapping genetics of numerous traits and disorders, although none to date has implicated shared polygenic risk between neurodegenerative and neuropsychiatric disease. Here, we apply several techniques to identify and dissect the polygenic overlap between ALS and schizophrenia. We provide evidence for genetic correlation between the two disorders which is unlikely to be driven by diagnostic misclassification and we demonstrate a lack of polygenic overlap between ALS and other neuropsychiatric and neurological conditions, which could be due to limited power given the smaller cohort sizes for these studies.

**Results**

**Genetic correlation between ALS and schizophrenia.** To investigate the polygenic overlap between ALS and schizophrenia, we used individual-level and summary data from GWAS for ALS (36,052 individuals) and schizophrenia (79,845 individuals). At least 5,582 control individuals were common to both datasets, but for some cohorts included in the schizophrenia dataset this could not be ascertained so this number is likely to be higher. For ALS, we used summary data from both mixed linear model association testing and meta-analysis of cohort-level logistic regression. We first used linkage disequilibrium (LD) score regression with ALS and schizophrenia summary statistics; this technique models, for polygenic traits, a linear relationship between a SNP’s LD score (the amount of genetic variation that it captures) and its GWAS test statistic. This distinguishes confounding from polygenicity in GWAS inflation and the regression coefficient can be used to estimate the SNP-based heritability ($h^2_S$) for single traits. In the bivariate case, the regression coefficient estimates genetic covariance ($\rho_p$) for pairs of traits, from which genetic correlation ($r_g$) is estimated; these estimates are unaffected by sample overlap between traits. Using constrained intercept LD score regression with mixed linear model ALS summary statistics, we estimated the liability-scale SNP-based heritability of ALS to be 8.2% (95% confidence interval $= 7.2$–$9.1$; mean $\chi^2 = 1.13$; all ranges reported below indicate 95% confidence intervals), replicating previous estimates based on alternative methods. Estimates based on ALS meta-analysis summary statistics and free-interpret LD score regression with mixed linear model summary statistics were lower (Supplementary Table 1), resulting in higher genetic correlation estimates (Supplementary Table 2); for this reason, we conservatively use constrained intercept genetic correlation estimates for ALS mixed linear model summary statistics throughout the remainder of this paper. Heritability estimates for permuted ALS data were null (Supplementary Table 1).

LD score regression estimated the genetic correlation between ALS and schizophrenia to be 14.3% ($7.05$–$21.6$; $P = 1 \times 10^{-4}$). Results were similar for a smaller schizophrenia cohort of 23,856 individuals, indicating that the inclusion of individuals of Asian ancestry in the schizophrenia cohort did not bias this result (Supplementary Fig. 1). In addition to schizophrenia, we estimated genetic correlation with ALS using GWAS summary statistics for bipolar disorder, major depressive disorder, attention deficit-hyperactivity disorder, autism spectrum disorder, Alzheimer’s disease (Supplementary Note 1), multiple sclerosis and adult height, finding no significant genetic correlation between ALS and any secondary trait other than schizophrenia (Fig. 1; Supplementary Table 2).

**Polygenic risk score analysis.** We supported the positive genetic correlation between ALS and schizophrenia by analysis of...
polygenic risk for schizophrenia in the ALS cohort. Polygenic risk scores (PRS) are per-individual scores based on the sum of alleles associated with one phenotype, weighted by their effect size, measured in an independent target sample of the same or a different phenotype\(^ {10}\). PRS calculated on schizophrenia GWAS summary statistics for twelve \( P \)-value thresholds (\( P_T \)) explained up to 0.12% (\( P_T = 0.2, \Delta \text{Explained variance} = 8.4 \times 10^{-7} \)) of the phenotypic variance in a subset of the individual-level ALS genotype data that had all individuals removed that were known or suspected to be present in the schizophrenia cohort (Fig. 2; Supplementary Table 5). ALS cases had on average higher PRS for schizophrenia compared to healthy controls and harbouring a high schizophrenia PRS for \( P_T = 0.2 \) significantly increased the odds of being an ALS patient in our cohort (Fig. 3; Supplementary Fig. 2). Values are provided in Supplementary Table 5.

Modelling misdiagnosis and comorbidity. Using BUHMBOX\(^ {21}\), a tool that distinguishes true genetic relationships between diseases (pleiotropy) from spurious relationships resulting from heterogeneous mixing of disease cohorts, we determined that misdiagnosed cases in the schizophrenia cohort (for example, young-onset FTD–ALS) did not drive the genetic correlation estimate between ALS and schizophrenia (\( P = 0.94 \)). Assuming a true genetic correlation of 0%, we estimated the required rate of misdiagnosis of ALS as schizophrenia to be 4.86% (2.47–7.13) to obtain the genetic correlation estimate of 14.3% (7.05–21.6; Supplementary Table 7), which we consider to be too high to be likely. However, if ALS and schizophrenia are genetically correlated, more comorbidity would be expected than if the genetic correlation was 0%. Modelling our observed genetic correlation of 14.3% (7.05–21.6), we estimated the odds ratio for having above-threshold liability for schizophrenia given above-threshold liability for schizophrenia to be 1.17 (1.08–1.26), and the same for schizophrenia given ALS (Supplementary Fig. 4). From a clinical perspective, to achieve 80% power to detect a significant (\( \alpha = 0.05 \)) excess of schizophrenia in the ALS cohort as a result of this genetic correlation, the required population-based incident cohort size is 16,448 ALS patients (7,310–66,670).

Figure 2 | Analysis of PRS for schizophrenia in a target sample of 10,032 ALS cases and 16,627 healthy controls. \( P \)-value thresholds (\( P_T \)) for schizophrenia SNPs are shown on the \( x \)-axis, where the number of SNPs increases with a more lenient \( P_T \). \( \Delta \text{Explained variances (Nagelkerke } R^2 \text{)} \) explained variance per \( P_T \) (red dots) represent \( P \)-values from the binomial logistic regression of ALS phenotype on PRS, accounting for LD (Supplementary Table 4) and including sex and significant principal components as covariates (Supplementary Fig. 2). Values are provided in Supplementary Table 5.

Figure 3 | Odds ratio for ALS by PRS deciles for schizophrenia. The figure applies to schizophrenia \( P \)-value threshold (\( P_T \)) = 0.2. The PRS for this threshold were converted to ten deciles containing near identical numbers of individuals. Decile 1 contained the lowest scores and decile 10 contained the highest scores, where decile 1 was the reference and deciles 2-10 were dummy variables to contrast to decile 1 for OR calculation. The case:control ratio per decile is indicated with grey bars. Error bars indicate 95% confidence intervals. Significant differences from decile 1 were determined by logistic regression of ALS phenotype on PRS decile, including sex and principal components as covariates and are indicated by *\( P<0.05 \) or ***\( P<0.001 \).
Pleiotropic risk loci. We leveraged the genetic correlation between ALS and schizophrenia to discover novel ALS-associated genomic loci by conditional false discovery rate (cFDR) analysis22 (Fig. 4; Supplementary Table 8). Five loci already known to be involved in ALS were identified (corresponding to MOBP, C9orf72, TBK1, SARM1 and UNC13A) along with five potential novel loci at cFDR < 0.01 (CNTN6, TNIP1, PPP2R2D, NCKAP5L and ZNF295-AS1). No gene set was significantly enriched (after Bonferroni correction) in genome-wide cFDR values when analysed using MAGENTA.

Discussion

There is evolving clinical, epidemiological and biological evidence for an association between ALS and psychotic illness, particularly schizophrenia. Genetic evidence of overlap to date has been based primarily on individual genes showing Mendelian inheritance, in particular the C9orf72 hexanucleotide repeat expansion, which is associated with ALS and FTD, and with psychosis in relatives of ALS patients2. In this study, we have replicated SNP-based heritability estimates for ALS and schizophrenia using GWAS summary statistics, and have for the first time demonstrated significant overlap between the polygenic components of both diseases, estimating the genetic correlation to be 14.3%. We have carefully controlled for confounding bias, including population stratification and shared control samples, and have shown through analysis of polygenic risk scores that the overlapping polygenic risk applies to SNPs that are modestly associated with both diseases. Given that our genetic correlation estimate relates to the polygenic components of ALS ($h^2 = 8.2\%$) and schizophrenia ($h^2 = 23\%$) and these estimates do not represent all heritability for both diseases, the accuracy of using schizophrenia-genetic risk-increasing and protective alleles is consistently aligned between ALS and schizophrenia, suggesting convergent biological mechanisms between the two diseases.

Although phenotypically heterogeneous, both ALS and schizophrenia are clinically recognizable as syndromes23,24. The common biological mechanisms underlying the association between the two conditions are not well understood, but are likely associated with disruption of cortical networks. Schizophrenia is a polygenic neurodevelopmental disorder characterized by a combination of positive symptoms (hallucinations and delusions), negative symptoms (diminished motivation, blunted affect, reduction in spontaneous speech and poor social functioning) and impairment over a broad range of cognitive abilities25. ALS is a late onset complex genetic disease characterized by a predominantly motor phenotype with recently recognized extra-motor features in 50% of patients, including cognitive impairment1. It has been suggested that the functional effects of risk genes in schizophrenia converge by modulating synaptic plasticity, and influencing the development and stabilization of cortical microcircuitry26. In this context, our identification of CNTN6 (contactin 6, also known as NB-3, a neural adhesion protein important in axon development)26 as a novel pleiotropy-informed ALS-associated locus supports neural network dysregulation as a potential convergent mechanism of disease in ALS and schizophrenia.

No significantly enriched biological pathway or ontological term was identified within genome-wide cFDR values using MAGENTA. Low inflation in ALS GWAS statistics, coupled with a rare variant genetic architecture2, render enrichment-based biological pathway analyses with current sample sizes challenging. Nevertheless, nine further loci were associated with ALS risk at cFDR < 0.01. Of these, MOBP, C9orf72, TBK1, SARM1 and UNC13A have been described previously in ALS and were associated by cFDR analysis in this study owing to their strong association with ALS through GWAS7. The remaining four loci (TNIP1, PPP2R2D, NCKAP5L and ZNF295-AS1) are novel associations and may represent pleiotropic disease loci. TNIP1 encodes TNFAIP3 interacting protein 1 and is involved in autoimmune and tissue homoeostasis27. The protein product of PPP2R2D is a regulatory subunit of protein phosphatase 2 and has a role in PI3K-Akt signalling and mitosis28. NCKAP5L is a homologue of NCKAP5, encoding NAP5, a proline-rich protein that has previously been implicated in schizophrenia, bipolar disorder and autism29,30. ZNF295-AS1 is a noncoding RNA31. Further investigation into the biological roles of these genes may yield novel insight into the pathophysiology of certain subtypes of ALS and schizophrenia, and as whole-genome and exome datasets become available in the future for appropriately large ALS case–control cohorts, testing for burden of rare genetic variation across these genes will be particularly instructive, especially given the role that rare variants appear to play in the pathophysiology of ALS7.

---

**Figure 4 | Pleiotropy-informed ALS risk loci determined by analysis of cFDR in ALS GWAS P-values given schizophrenia GWAS P-values (cFDRALS < cFDRSZ).** Each point denotes a SNP; its x axis position corresponds to its chromosomal location and its height indicates the extent of association with ALS by cFDR analysis. The solid line indicates the threshold cFDR = 0.01. Any gene whose role in ALS is already established is in bold. A complete list of all loci at cFDR ≤ 0.05 is provided in Supplementary Table 8.
Our data suggest that other neuropsychiatric conditions (bipolar disorder, autism and major depression) do not share polygenic risk with ALS. This finding contrasts with our recent observations from family aggregation studies and may be unexpected given the extensive genetic correlation between neuropsychiatric conditions. This could relate to statistical power conferred by secondary phenotype cohort sizes, and future studies with larger sample sizes will shed further light on the relationship between ALS and neuropsychiatric disease. It is also possible that the current study underestimates genetic correlations due to the substantial role that rare variants play in the genetic architecture of ALS and future fine-grained studies examining heritability and genetic correlation in low-minor allele frequency and low-LD regions may identify a broader relationship between ALS and neuropsychiatric diseases.

A potential criticism of this study is that the polygenic overlap between ALS and schizophrenia could be driven by misdiagnosis, particularly in cases of ALS–FTD, which can present in later life as a psychotic illness and could be misdiagnosed as schizophrenia. This is unlikely, as strict diagnostic criteria are required for inclusion of samples in the schizophrenia GWAS dataset. Furthermore, since core schizophrenia symptoms are usually diagnosed during late adolescence, a misdiagnosis of FTD-onset ALS–FTD as schizophrenia is unlikely. In this study, we found no evidence for misdiagnosis of ALS as schizophrenia (BUHMBOX P = 0.94) and we estimated that a misdiagnosis of 3.8% of ALS cases would be required to spuriously observe a genetic correlation of 0.1%, which is not likely to occur in clinical practice. We are therefore confident that this genetic correlation estimate reflects a genuine polygenic overlap between the two diseases and is not a feature of cohort ascertainment, but the possibility of some misdiagnosis in either cohort cannot be entirely excluded based on available data.

A positive genetic correlation between ALS and schizophrenia predicts an excess of patients presenting with both diseases. Most neurologists and psychiatrists, however, will not readily acknowledge that these conditions co-occur frequently. Our genetic correlation estimate confers an odds ratio of 1.036 (95% CI 0.985–1.096) for harbouring above-threshold liability for ALS given schizophrenia (or vice versa) and a lifetime risk of 1:34,336 (1.08–1.26) for harbouring above-threshold liability for ALS in the schizophrenia GWAS controls from the schizophrenia GWAS (Psychiatric Genomics Consortium) and dbGaP accession number phs000213.v3.p2. Using 88,971 LD-pruned (window size 200 SNPs; shift 20 SNPs; r² > 0.25) SNPs in both datasets (INFO score > 0.8; MAF > 0.2), with SNPs in high-LD regions removed (Supplementary Table 4), samples were removed from the ALS dataset if they were duplicated or had a cryptically related counterpart (PLINK r > 0.1; 5,582 individuals) in the schizophrenia cohort and whole strata (representing Finnish and German samples; 3,811 individuals) were also removed if commonality with the schizophrenia cohort could not be ascertained (due to unavailability of individual-level genotypic data in the schizophrenia cohort) and in which a sample overlap was suspected (Supplementary Table 3).

**LD score regression.** We calculated LD scores using LDSC v1.0.0 in 1 centiMorgan windows around 13,307,412 non-singleton variants genotyped in 379 European individuals (CEU, FIN, GBR, IBS and TSI populations) in the phase 1 integrated release of the 1,000 Genomes Project. For regression weights, we restricted LD score calculation to SNPs included in both the GWAS summary statistics and HapMap phase 3; for r² estimation in pairs of traits this was the intersection of SNPs for both traits and HapMap. Because population structure and confounding were highly controlled in the ALS summary statistics by the use of mixed linear model association testing implemented in Genome-wide Complex Trait Analysis or logistic regression combined with cross-stratum meta-analysis using METAL, we estimated that a misdiagnosis of 4.86% of ALS cases would be required to spuriously observe a genetic correlation of 14.3%, which is not likely to occur in clinical practice. We are therefore confident that this genetic correlation estimate reflects a genuine polygenic overlap between the two diseases and is not a feature of cohort ascertainment, but the possibility of some misdiagnosis in either cohort cannot be entirely excluded based on available data.

A positive genetic correlation between ALS and schizophrenia predicts an excess of patients presenting with both diseases. Most neurologists and psychiatrists, however, will not readily acknowledge that these conditions co-occur frequently. Our genetic correlation estimate confers an odds ratio of 1.036 (95% CI 0.985–1.096) for harbouring above-threshold liability for ALS given schizophrenia (or vice versa) and a lifetime risk of 1:34,336 (1.08–1.26) for harbouring above-threshold liability for ALS in the schizophrenia GWAS controls from the schizophrenia GWAS (Psychiatric Genomics Consortium and dbGaP accession number phs000213.v3.p2). Using 88,971 LD-pruned (window size 200 SNPs; shift 20 SNPs; r² > 0.25) SNPs in both datasets (INFO score > 0.8; MAF > 0.2), with SNPs in high-LD regions removed (Supplementary Table 4), samples were removed from the ALS dataset if they were duplicated or had a cryptically related counterpart (PLINK r > 0.1; 5,582 individuals) in the schizophrenia cohort and whole strata (representing Finnish and German samples; 3,811 individuals) were also removed if commonality with the schizophrenia cohort could not be ascertained (due to unavailability of individual-level genotypic data in the schizophrenia cohort) and in which a sample overlap was suspected (Supplementary Table 3).

**Polymetric risk score analysis.** We calculated PRS for 10,032 cases and 16,627 healthy controls in the ALS dataset (duplicates and suspected or confirmed duplicates removed) and samples with the schizophrenia dataset removed to estimate schizophrenia-associated alleles and effect sizes reported in the GWAS summary statistics for 6,843,674 SNPs included in both studies and in the phase 1 integrated release of the 1,000 Genomes Project (imputation INFO score < 0.3; minor allele frequency < 0.01; A/T and G/C SNPs removed). SNPs were clumped in two rounds (physical distance threshold of 250 kb and a LD threshold of 0.5 in the first round and a distance of 5,000 kb and LD threshold of 0.2 in the second round) using PLINK v1.90b3y, removing high-LD regions (Supplementary Table 4), resulting in a final set of 496,548 SNPs for PRS calculations. Odds ratios for autosomal SNPs reported in the schizophrenia summary statistics were log-converted to beta values and PRS were calculated using PLINK’s score function for twelve schizophrenia GWAS P-value thresholds (P (r): 5 × 10⁻⁵, 5 × 10⁻⁶, 5 × 10⁻⁷, 5 × 10⁻⁸, 5 × 10⁻⁹, 5 × 10⁻¹⁰, 5 × 10⁻¹¹, 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5. A total of 100 principal components (PCs) were generated for the ALS sample using GCTA version 1.24.4. Using R version 3.2.2, a generalized linear model was applied to model the phenotype of individuals in the ALS dataset. PCs that had a significant effect on the phenotype (P < 0.0005, Bonferroni-corrected for 100 PCs) were selected (PCs 1, 4, 5, 7, 8, 10, 11, 12, 14, 36, 49).
To estimate explained variance of PRS on the phenotype, a baseline linear relationship including only sex and significant PCs as variables was modelled first: 

\[ y = \beta_0 + \beta_{sex} \times sex + \sum_n \beta_{PC_n} \times PC_n, \]

where \( y \) is the phenotype in the ALS dataset, \( x \) is the intercept of the model with a slope \( \beta \) for each variable \( x \).

Subsequently, a linear model including polygenic scores for each schizophrenia \( P_{rs} \) was calculated:

\[ y = \beta_0 + \beta_{sex} \times sex + \sum_n \beta_{PC_{n,rs}} \times PC_{n,rs} + \beta_{PC_{rs}} \times PC_{rs}. \]

A Nagelkerke \( R^2 \) value was obtained for every model and the baseline Nagelkerke \( R^2 \) value was subtracted, resulting in a \( R^2 \) explained variance that describes the contribution of schizophrenia-based PRS to the phenotype in the ALS dataset. PRS analysis was also performed in permutated case-control data (1,000 permutations), conserving case–control ratio to assess whether the increased \( R^2 \) explained variance was a true signal associated with phenotype. \( R^2 \) explained variances and \( P \)-values were averaged across permutation analyses.

To ensure we did not over- or under-correct for population effects in our model, we tested the inclusion of up to a total of 30 PCs in the model, starting with the PC with the most significant effect on the ALS phenotype (Supplementary Fig. 2). Increasing the number of PCs initially had a large effect on the \( R^2 \) explained variance, but this effect levelled out after 11 PCs. On the basis of this test we are confident that adding the 11 PCs that had a significant effect on the phenotype sufficiently accounted for population differences. For the schizophrenia \( P_{rs} \) for which we obtained the highest \( R^2 \) explained variance (0.2), we subdivided observed schizophrenia-based PRS in the ALS cohort into deciles and calculated the odds ratio for being an ALS case in each decile compared to the first decile using a similar generalized linear model:

\[ y = \beta_0 + \beta_{sex} \times sex + \sum_n \beta_{PC_{n,rs}} \times PC_{n,rs} + \beta_{PC_{rs,decile}} \times PC_{rs,decile}. \]

Odds ratios and 95% confidence intervals for ALS were derived by calculating the exponential function of the beta estimate of the model for each of the deciles 2–10.

**Diagnostic misclassification.** To distinguish the contribution of misdiagnosis from true genetic pleiotropy we used BHUMBOX21 with 417 independent ALS risk alleles in a sample of 27,647 schizophrenia patients for which individual-level GWAS summary statistics were available. We also estimated the required misdiagnosis rate \( M \) of FTD–ALS as schizophrenia that would lead to the observed genetic correlation estimate as \( C/C' = 1 \), where \( C = \rho_{PC_{FTD,ALS}} \) and \( C' = \rho_{PC_{FTD,ALS}} \), which are the number of cases in the schizophrenia and ALS datasets, respectively22 (derived in Supplementary Methods 1).

**Expected comorbidity.** To investigate the expected comorbidity of ALS and schizophrenia given the observed genetic correlation, we modelled the distribution in liability for ALS and schizophrenia as a bivariate normal distribution with the liability-scale covariance determined by LD score regression (Supplementary in liability for ALS and schizophrenia as a bivariate normal distribution with the sufficiently accounted for possible confounding due to population differences.

Using an adapted cFDR method9 that conserving case–control ratio) to assess whether the increased contribution of schizophrenia-based PRS to the phenotype in the ALS dataset. PRS summary statistics were residualized on LD score by subtracting the product of each SNP’s LD score and the univariate LD and GWAS test statistics, schizophrenia summary statistics were residualized on LD score by subtracting the product of each SNP’s LD score and the univariate LD score test to assess gene-set enrichment39.

**Pleiotropy-informed risk loci for ALS.** Using an adapted cFDR method9 that allows shared controls between cohorts25, we estimated per-SNP cFDR given LD score corrected26 schizophrenia GWAS \( P \)-values for ALS mixed linear model summary statistics calculated in a dataset excluding Finnish and German cohorts (in which suspected control overlap could not be determined), but including all other available controls (totaling 5,882). To correct for the relationships between LD and GWAS test statistics, schizophrenia summary statistics were residualized on LD score by subtracting the product of each SNP’s LD score and the univariate LD score regression coefficient for schizophrenia. cFDR values conditioned on these residualized schizophrenia GWAS \( P \)-values were calculated for mixed linear model association statistics calculated at 6,843,670 SNPs genotyped in 10,147 ALS cases and 22,094 controls. Pleiotropic genomic loci were considered statistically significant if cFDR < 0.01 (following Andressen et al26) and were clumped with all neighbouring SNPs based on \( r^2 \geq 0.1 \) in the complete ALS dataset. Associated cFDR genomic regions were then mapped to the locations of known RefSeq transcripts in human genome build GRCh37. Genome-wide cFDR values were also tested for enrichment in 9,711 gene sets included in the MAGENTA software package (version 2.4, July 2011) and derived from databases such as Gene Ontology (GO, http://geneontology.org/), Kyoto Encyclopedia of Genes and Genomes (KEGG, http://www.kegg.jp/), Protein ANalysis Through Evolutionary Relationships (PANTHER, http://www.pantherdb.org/) and INGENUITY (http://www.ingenuity.com/). SNPs were mapped to genes including 20 kb up- and downstream regions to include regulatory elements. The enrichment cutoff applied in our analysis was based on the 95th percentile of gene scores for all genes in the genome. The null distribution of gene scores for each gene set was based on 10,000 randomly sampled gene sets with equal size. MAGENTA uses a Mann–Whitney rank-sum test to assess gene-set enrichment39.

**References**

1. Phukan, J. et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J. Neurol. Neurosurg. Psychiatry 83, 102–108 (2012).

2. Byrne, S. et al. Aggregation of neurologic and neuropsychiatric disease in amyotrophic lateral sclerosis kindreds: a population-based case–control cohort study of familial and sporadic amyotrophic lateral sclerosis. Ann. Neurol. 74, 828–840 (2013).

3. Al-Chalabi, A. et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J. Neurol. Neurosurg. Psychiatry 81, 1324–1326 (2010).

4. Lichtenstein, P. et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet Lond. Engl. 373, 234–239 (2009).

5. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421–427 (2014).

6. Cross-Disorder Group of the Psychiatric Genomics Consortium. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat. Genet. 45, 984–994 (2013).

7. van Rhijn, W. et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat. Genet. 48, 1043–1048 (2016).

8. Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases and traits. Nat. Genet. 47, 1236–1241 (2015).

9. Andreassen, O. A. et al. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Ann. J. Hum. Genet. 92, 197–209 (2013).

10. International Schizophrenia Consortium. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460, 748–752 (2009).

11. van Rhijn, W. et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat. Genet. 48, 1043–1048 (2016).

12. Wilcer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190–21910 (2010).

13. Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat. Genet. 47, 291–295 (2015).

14. Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium. Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 43, 969–976 (2011).

15. Psychiatric GWAS Consortium Bipolar Disorder Working Group. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat. Genet. 43, 977–983 (2011).

16. Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium. A mega-analysis of genome-wide association studies for major depressive disorder. Mol. Psychiatry 18, 497–511 (2013).

17. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet Lond. Engl. 381, 1371–1379 (2013).

18. Lambert, J. C. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat. Genet. 45, 1452–1458 (2013).

19. Patsopoulos, N. A. et al. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann. Neurol. 70, 897–912 (2011).

20. Wood, A. R. et al. Defining the role of common variation in the genomic and biological architecture of adult human height. Nat. Genet. 46, 1173–1186 (2014).

21. Han, B. et al. A method to decipher pleiotropy by detecting underlying heterogeneity driven by hidden subgroups applied to autoimmune and neuropsychiatric diseases. Nat. Genet. 48, 803–810 (2016).

22. Liley, J. & Wallace, C. A pleiotropy-informed Bayesian false discovery rate adapted to a shared control design finds new disease associations from GWAS summary statistics. PLoS Genet. 11, e1004926 (2015).

23. Brown, A. S. & McGrath, J. J. The prevention of schizophrenia. Schizophr. Bull. 37, 57–261 (2011).

24. Al-Chalabi, A. et al. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 15, 1182–1194 (2016).

25. Kahn, R. S. et al. Schizophrenia. Nat. Rev. Dis. Primer 1, 15067 (2015).
26. Huang, Z., Yu, Y., Shimoda, Y., Watanabe, K. & Liu, Y. Loss of neural recognition molecule NB-3 delays the normal projection and terminal branching of developing corticospinal tract axons in the mouse. J. Comp. Neurol. 520, 1227–1245 (2012).

27. Ramirez, V. P., Gurevich, I. & Aneskievich, B. J. Emerging roles for TNIP1 in regulating post-receptor signaling. Cytokine Growth Factor Rev. 23, 109–118 (2012).

28. Toker, A. & Marmirol, S. Signaling specificity in the Akt pathway in biology and disease. Adv. Biol. Regul. 55, 28–38 (2014).

29. Wang, K.-S., Liu, X.-F. & Aragam, N. A genome-wide meta-analysis identifies novel loci associated with schizophrenia and bipolar disorder. Schizophr. Res. 124, 192–199 (2010).

30. Chahrouf, M. H. et al. Whole-exome sequencing and homoyzogosity analysis implicate depolarization-regulated neuronal genes in autism. PLoS Genet. 8, e1002635 (2012).

31. Ota, T. et al. Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat. Genet. 36, 40–45 (2004).

32. Laursen, T. M., Munk-Olsen, T. & Vestergaard, M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr. Opin. Psychiatry 25, 83–88 (2012).

33. Stommel, E. W., Graber, D., Montanye, J., Cohen, J. A. & Harris, B. T. Does treating schizophrenia reduce the chances of developing amyotrophic lateral sclerosis? Med. Hypotheses 69, 1021–1028 (2007).

34. Farokhnia, M. et al. A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. Psychopharmacology 231, 533–542 (2014).

35. McVean, G. A. et al. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56–65 (2012).

36. Patterson, N., Price, A. L. & Reich, D. Population structure and eigenanalysis. PLoS Genet. 2, e190 (2006).

37. Wray, N. R., Lee, S. H. & Kendler, K. S. Impact of diagnostic classification on the formation of genetic correlations using genome-wide genotypes. Eur. J. Hum. Genet. 20, 668–674 (2012).

38. Johnston, C. A. et al. Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J. Neurol. 253, 1642–1643 (2006).

39. Segovia, A. V. et al. Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. PLoS Genet. 6, e1001058 (2010).

Acknowledgements

We acknowledge helpful contributions from Mr Gert Jan van de Vendel in the design and execution of PRS analyses. This study received support from the ALS Association; Fondation Thierry Latran; the Motor Neurone Disease Association of England, Wales and Northern Ireland; Science Foundation Ireland; Health Research Board (Ireland); The Netherlands ALS Foundation (Project MinE); to J.H.V., L.H.v.d.B.; The Netherlands Organisation for Health Research and Development (Vici scheme, L.H.v.d.B.) and ZonMW under the frame of E-Rare-2, the ERA Net for Research on Rare Diseases (PYRAMID). Research leading to these results has received funding from the European Community’s Health Seventh Framework Programme (FP7/2007–2013). A.G. is supported by the Research Foundation KU Leuven (C24/16/045). A.A.-C. received salary support from the National Institute for Health Research (NIHR) Dementia Biomedical Research Unit and Biomedical Research Centre in Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Samples used in this research were in part obtained from the UK National DNA Bank for MND Research, funded by the MND Association and the Wellcome Trust. We acknowledge sample management undertaken by Biobanking Solutions supported by the Medical Research Council (MRC) at the Centre for Integrated Genomic Medicine, University of Manchester. This is an EU Joint Programme-Neurodegenerative Disease Research (IPND) Project (STRENGTH, SOPHIA). In addition to those mentioned above, the project is supported through the following funding organizations under the aegis of IPND: UK, Economic and Social Research Council, Italy, Ministry of Health and Ministry of Education, University and Research; France, L’Agence nationale pour la recherche. The work leading up to this publication was supported by the European Community’s Health Seventh Framework Programme (FP7/2007–2013; Grant Agreement Number 259,867). We thank the International Genomics of Alzheimer’s Project (IGAP) for providing summary results data for these analyses. The investigators within IGAP provided data but did not participate in analysis or writing of this report. IGAP was made possible by the generous participation of the control subjects, the patients, and their families. The i-Select chips was funded by the French National Foundation on Alzheimer’s disease and related disorders. EADI was supported by the LABEX (laboratory of excellence program investment for the future) DISTALZ grant, Inserm, Institut Pasteur de Lille, Université de Lille 2 and the Lille University Hospital. GERAD was supported by the MRC (Grant No. 5,03,400), Alzheimer’s Research UK (Grant No. 5,03,176), the Wellcome Trust (Grant No. 082604/20/7/Z) and German Federal Ministry of Education and Research: Competence Network Dementia Grant no. 01GI0102, 01GI0711, 01GI0420. CHARITY was partly supported by the NIH/NIA Grant R01 AG033193 and the NIA AG081220 and AGES contract N01-AG-12,100, the NHLBI Grant R01 HL105756, the Icelandic Heart Association, and the Erasmus Medical Center and Erasmus University. ADGC was supported by the NIH/NIA Grants: U01 AG032984, U24 AG021886, U01 AG06976, and the Alzheimer’s Association Grant ADGC-10–196728. The Project MinE GWAS Consortium included contributions from the PARALS registry, SLALOM group, SLAP registry, FAIS Sequencing Consortium, SLAGEN Consortium and NINNPS Study Group, the Schizophrenia Working Group of the Psychiatric Genomics Consortium included contributions from the Psychosis Endophenotypes International Consortium and Wellcome Trust Case–control Consortium. Members of these eight consortia are listed in Supplementary Note 2.

Author contributions

O.H., J.H.V. and A.A.-C. conceived the study. R.L.McL., D.S., W.v.R., K.R.v.E., M.O’B., D.G.B., AA.-C., L.H.v.d.B., J.J.L., O.H. and J.H.V. contributed to study design. R.L.McL., D.S. and W.v.R. conducted the analyses. R.L.McL., D.S., O.H., J.J.L. and J.H.V. drafted the manuscript. R.S.K., R.A.O. and A.G. provided data and critical revision of the manuscript. The Project MinE GWAS Consortium and Schizophrenia Working Group of the Psychiatric Genomics Consortium provided data. R.L.McL. and D.S. contributed equally. J.J.L., O.H. and J.H.V. jointly directed the work.

Additional information

Supplementary Information accompanies this paper at http://www.nature.com/ncomms.

Competing interests: O.H. has received speaking honoraria from Novartis, Biogen Idec, Sanofi Aventis and Merck-Serono. She has been a member of advisory panels for Biogen Idec, Allergen, Ono Pharmaceuticals, Novartis, Cytokinetics and Sanofi Aventis. She serves as Editor-in-Chief of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. L.H.v.d.B. serves on scientific advisory boards for Primes Beatrix Spierfonds, Thierry Latran Foundation, Baxalta, Cytokinetics and Biogen, serves on the Editorial Board of the Journal of Neurology, Neurosurgery, and Psychiatry, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, and Journal of Neuromuscular Diseases. A.A.C. has served on advisory panels for Biogen Idec, Cytokinetics, GSK, OrionPharma and Mitsubishi Tanabe, serves on the Editorial Boards of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration and F1000, and receives royalties for The Brain: A Beginner’s Guide, OneWorld Publications, and Genetics of Complex Human Diseases, Cold Spring Harbor Laboratory Press. The remaining authors declare no competing financial interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

How to cite this article: McLaughlin, R. L. et al. Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. Nat. Commun. 8, 14774 doi: 10.1038/ncomms14774 (2017).

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Project MinE GWAS Consortium

Aleksey Shatunov8, Annelot M. Dekker3, Frank P. Diekstra3, Sara L. Pulit4, Rick A.A. van der Spek3, Perry T.C. van Doormaal3, William Sproviero8, Ashley R. Jones8, Garth A. Nicholson10,11, Dominic B. Rowe10, Roger Pamphlett12, Matthew C. Kiernan13, Denis Bauer14, Tim Kahlke14, Kelly Williams10, Filip Eftimov15, Isabella Fogh8,16, Nicola Ticozzi16,17, Kuang Lin8, Stéphanie Millecamps18, François Salachas19, Vincent Meiningers19, Mamede de Carvalho20,21, Susana Pinto20,21, Jesus S. Mora22, Ricardo Rojas-Garcia23, Meralda Polak24, Siddharthan Chandran25,26, Shuna Colville25, Robert Swingler25, Karen E. Morrison27,28, Pamela J. Shaw29, John Hardy30, Richard W. Orrell31, Alan Pittman30,32, Katie Sidle31, Pietro Fratta33, Andrea Malaspina34,35, Susanne Petri36, Susanna Abdulla37, Carsten Drepper38, Michael Sendtner38, Thomas Meyer39, Martina Wiedau-Pazos5, Catherine Lomen-Hoerth40, Vivianna M. Van Deerlin41, John Q. Trojanowski41, Lauren Elman42, Leo McCluskey42, Nazi Basak43, Thomas Meitinger44, Peter Lichtner44, Milena Blagojevic-Radivojkov44, Christian R. Andres45, Cindy Maurel45, Gilbert Bensimon46, Bernhard Landwehrmeyer47, Alexis Brice48, Christine A.M. Payan46, Safa Saker-Delye49, Alexandra Dürs50, Nicholas Wood51, Lukas Tittmann52, Wolfgang Lieb52, Andre Franke53, Marcella Rietzschel54, Sven Cichon55,56,57,58,59, Markus M. Nöthen55,56, Philippe Amouyel60, Christophe Tzourio61, Jean-François Dartigues61, Andre G. Uitterlinden62,63, Fernando Rivadeneira62,63, Karol Estrada62, Albert Hofman63, Charles Curtis64, Anneke J. van der Kooi65, Marianne de Visser65, Markus Weber65, Christopher E. Shaw8, Bradley N. Smith8, Orietta Pansarasa66, Cristina Cereda66, Roberto Del Bo67, Giacomo P. Com67, Sandra D’Alfonso68, Cinzia Bertolin69, Gianni Soraru69, Letizia Mazzini70, Viviana Pensato71, Cinzia Gellera71, Cinzia Tilco16, Antonia Ratti16,17, Andrea Calvo72,73, Cristina Moglia72,73, Maura Brunetti72,73, Simon Arcuti74, Rosa Capozzo74, Chiara Zecca74, Christian Lunetta75, Silvana Penco76, Nilo Riva77, Alessandro Padovani78, Massimiliano Filosto78, Ian Blair10, P. Nigel Leigh79, Federico Casale87, Adriano Chio72,73, Ettore Beghi80, Elisabetta Pupillo80, Rosanna Tortelli74, Giancarlo Logroscino81,82, John Powell8, Albert C. Ludolph47, Jochen H. Weishaupt47, Wim Robberecht83, Philip Van Damme83,84, Robert H. Brown85, Jonathan Glass24, John E. Landers85, Peter M. Andersen46,86, Philippe Corcia87,88, Patrick Vourch45, Vincenzo Silani16,17, Michael A. van Es3, R. Jeroen Pasterkamp89, Cathryn M. Lewis90,91 & Gerome Breen6,92,93

10Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia. 11University of Sydney, ANZAC Research Institute, Concord Hospital, Sydney, New South Wales, Australia. 12The Stacey MND Laboratory, Department of Pathology, The University of Sydney, New South Wales, Australia. 13Brain and Mind Research Institute, The University of Sydney, New South Wales, Australia. 14Transformational Bioinformatics, Commonwealth Scientific and Industrial Research Organisation, Sydney, New South Wales, Australia. 15Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands. 16Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy. 17Department of Pathophysiology and Transplantation, ‘Dino Ferrari’ Center, Università degli Studi di Milano, Milano, Italy. 18Institut du Cerveau et de la Moelle épinière, INSERM U1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMRS1127, Paris, France. 19Ramsay General Hospital, Edinburgh, UK. 20Centre for Neuroregeneration and Medical Research Council Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK. 21Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia. 22Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia. 23Institute for Clinical Neurobiology, University of Wuerzburg, Wuerzburg, Germany. 24Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany. 25INSERM U930, Université François Rabelais, Tours, France. 26Centre for Neurology, Ulm University, Ulm, Germany. 27INSERM U 1127, CNRS UMR 7225, Sorbonne Universités, Paris, France. 28Genethon, CNRS UMR 8587 Evry, France. 29Department of Neurology, Humboldt-University, Berlin, Germany. 30Department of Neurology, University of California, San Francisco, California, USA. 31Centre for Neurodegenerative Disease Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 32Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 33Department of Neurology, Medical School Hannover, Hannover, Germany. 34Centre for Neuroregeneration and Medical Research Council Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK. 35North-East London and Essex Regional Motor Neuron Disease Care Centre, School of Medicine at the University of Pennsylvania, Pennsylvania, USA. 36Department of Neurology, Medical School Hannover, Hannover, Germany. 37Department of Neurology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany. 38Departments of Neurology and Neurosurgery, Westmead Hospital, Westmead, New South Wales, Australia. 39MRC Centre for Neurodegenerative Disease Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 40Department of Neurology, Humboldt-University, Berlin, Germany. 41Department of Neurology, University of California, San Francisco, California, USA. 42Centre for Neurodegenerative Disease Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 43Neurodegeneration Research Laboratory, Bogazici University, Istanbul, Turkey. 44Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany. 45INSERM U930, Université François Rabelais, Tours, France. 46APHP, Département de Pharmacologie Clinique, Hôpital de la Pitié-Salpétrière, UPMC Pharmacologie, Paris 6, Paris, France. 47Department of Neurology, ULM University, Ulm, Germany. 48INSERM U 1127, CNRS UMR 7225, Sorbonne Universités, Paris, France.
Schizophrenia Working Group of the Psychiatric Genomics Consortium

Stephan Ripke49,95, Benjamin M. Neale49,95,96,97, Aiden Corvin98, James T.R. Walters99, Kai-How Farh94, Peter A. Holmans99,100, Phil Lee94,95,97, Brendan Bulik-Sullivan94,95, David A. Collier101,102, Hailiang Huang94,96, Tune H. Pers96,103,104, Ingrid Agartz105,106,107, Esben Agerbo108,109,110, Margot Albus111, Madeline Alexander112, Farooq Amin113,114, Elizabeth Bevilacqua95, Tim B. Bigdeli115, Donald W. Black120, Richard Bruggeman121, Nancy G. Buocca122, Randy L. Buckner123,124,125, William Byerley126, Wipke Cahn4, Guiping Cai127,128, Dominique Campion129, Rita M. Cantor5, Vaughan J. Carr130,131, Noa Carrera99, Stanley V. Catts130,132, Kimberley D. Chambert95, Raymond C.K. Chan133, Ronald Y.L. Chan134, Eric Y.H. Chen134,135, Wei Cheng136, Eric F.C. Cheung137, Siow Ann Chong138, C. Robert Cloninger139, David Cohen140, Nadine Cohen141, Paul Cormican98, Nick Craddock99,100, James J. Crowley142, David Curtis143,144, Michael Davidson145, Kenneth L. Davis128, Franziska Degenhardt55,56, Jurgen Del Favero146, Ditte Demontis110,147,148, Dimitris Dikeos149, Timothy Dinan150, Srdjan Djurovic107,151, Gary Donohoe98,152, Elodie Drapeau128, Jubao Duan153,154, Frank Dudbridge155, Naser Durmishi156, Peter Eichhammer157, Johan Eriksson158,159,160, Valentina Esott-Price99, Laurent Essioux161, Ayman H. Fanous162,163,164,165, Martilias S. Farrell142, Josef Frank166, Lude Franke90, Robert Freedman167, Nelson B. Freimer5, Marion Fried168, Joseph I. Friedman128, Menachem Fromer94,95,97,169, Giulio Genovese95, Lyudmila Georgieva99, Ina Giegling168,170, Paola Giusti-Rodriguez142, Stephanie Godard171, Jacqueline I. Goldstein94,96, Vera Golimbet172, Srikante Gopal141, Jacob Gratten173, Lieuwe de Haan174, Christian Hammer116, Marian L. Hamshere99, Mark Hansen175, Thomas Hansen110,176, Vahram Haroutunian128,177,178, Annette M. Hartmann168, Frans A. Henskens130,179,180, Stefan Herms55,56,58, Joel N. Hirschhorn96,104,181, Per Hoffman55,56,58, Andrea Hofman55,56, Mads V. Hollegaard182, David M. Houghaard182, Masashi Ikeda183, Inge Joa184, Antonio Julia185, Luba Kalaydjieva186,187, Sena Karachanak-Yankova188, Juha Karjalainen90, David Kavanagh99,
Matthew C. Keller189, James L. Kennedy190,191,192, Andrey Khrunin193, Yunjung Kim142, Janis Klovins194, James A. Knowles195, Bettina Konte168, Vaidutis Kucinskas196, Zita Ausrele Kucinskienė196, Hana Kuzelova-Ptackova197,198, Anna K. Kähler119, Claudine Laurent112,199, Jimmy Lee138,200, S. Hong Lee173, Sophie E. Legge99, Bernard Lerer201, Miaoxin Li134,202, Tao Li203, Kung-Yee Liang204, Jeffrey Lieberman205, Svetlana Limborska193, Carmel M. Loughland130,206, Jan Lubinski207, Jouko Lönnqvist208, Milan Macel197,198, Patrik K.E. Magnusson19, Brion S. Maher209, Wolfgang Maier210, Jacques Mallet211, Sara Marsal185, Manuel Matthesen110,147,148,212, Morten Mattingsdal107,213, Robert W. McCarley214,215, Colm McDonald216, Andrew M. McIntosh217,218, Sandra Meieri169, Carin J. Meijer174, Bela Melegh117,118, Ingrid Melle170,219, Raquelle I. Mesholam-Gately214,215,220, Andres Metspalu221, Patricia T. Michie130,222, Lili Milani221, Vihra Milanova223, Younes Mokrab101, Derek W. Morris98,152, Ole Mors110,147,224, Kieran C. Murphy225, Robin M. Murray226, Inez Myin-Germeys227, Bertram Müller-Myhsok228,229,230, Mari Nelis221, Igor Nenadic231, Deborah A. Nertney232, Gerald Nestadt233, Kristin K. Nicodemus234, Liene Nikitina-Zake194, Laura Nisenbaum235, Annelie Nordin236, Eadbhard O’Callaghan237, Colm O’Dushlaine95, F. Anthony O’Neill238, Sang-Yun Oh239, Ann Olincy167, Line Olsen110,176, Jim Van Os227,240, Christos Pantelis130,241, George N. Papadimitriou149, Sergi Papiol116, Elena Parkhomenko128, Michele T. Paton195, Tiina Paunio242,243, Milica Pejovic-Milovancevic244, Diana O. Perkins245, Olli Pietiläinen243,246, Jonathan Pimm144, Andrew J. Pocklington99, Alkes Price247, Ann E. Pulver233, Shaun M. Purcell169, Digby Quested248, Henrik B. Rasmussen110,176, Abraham Reichenberg128, Mark A. Reimers249, Alexander L. Richards99,100, Joshua L. Roffman213,214, Panos Roussos169,250, Douglas M. Ruderfer169, Veikko Salomaa160, Alan R. Sanders153,154, Ulrich Schall130,206, Christian R. Schubert251, Thomas G. Schulze166,252, Sibylle G. Schwab253, Edward M. Scollnick95, Rodney J. Scott130,254,255, Larry J. Seidman214,220, Jianxin Shi256, Engilbert Sigurdsson257, Teimuraz Silagadze258, Jeremy M. Silverman128,259, Kang Sim138, Petr Sloomin193, Jordan W. Smoller95,107,176, Chris C. A. Spencer260, Eli A. Stahl96,169, Hreinn Stefansdottir261, Stacy Steinberg262, Elisabeth Stogmann263, Richard E. Straub263, Eric Strengman264,265, Jana Strohmaier166, T. Scott Stroup205, Mythily Subramaniam138, Jaana Suvisaari208, Dragan M. Svartik139, Jin P. Szatkiewicz142, Erik Söderman105, Srinivas Thirumalai266, Draga Toncheva188, Sarah Tosato267, Juha Veijola268,269, John Waddington270, Dermot Walsh271, Dai Wang141, Qiang Wang203, Bradley T. Webb115, Mark Weiser145, Dieter B. Wildenauer272, Nigel M. Williams273, Stephanie Williams142, Stephanie H. Witt166, Aaron R. Wolter249, Emily H.M. Wong134, Brandon K. Wormley115, Hualin Simon Xi274, Clement C. Zai190,191, Xuebin Zheng275, Fritz Zimprich262, Naomi R. Wray173, Kari Stefansson261, Peter M. Visscher261, Rolf Adolfsson236, Ole A. Andreassen107,219, Douglas H.R. Blackwood218, Elvira Bramon276, Joseph D. Buxbaum128,129,177,277, Anders D. Bögloff110,147,148,222, Ariel Darvasi278, Enrico Domenici279, Hannelore Ehrenreich116, Tõnu Esko96,104,181,221, Pablo V. Gejman153,154, Michael Gill98, Hugh Gurling144, Christina M. Hultman119, Nakao Iwata183, Assen V. Jablensky130,280,281,282, Erik G. Jönsson105, Kenneth S. Kendler283, George Kirov99, Jo Knight190,191,192, Todd Lencz284,285,286, Douglas F. Levinson112, Qingxin S. Li141, Jianjun Liu275,276, Anil K. Malhotra284,285,286, Steven A. McCarroll95,181, Andrew McQuillin144, Jennifer L. Moran95, Preben B. Mortensen108,109,110, Bryan J. Mowry173,288, Michael J. Owen99,100, Aarno Palotie97,98,246,289, Carlos N. Patin195, Tracey L. Petryshen214,289,290, Danielle Posthuma291,292,293, Brien P. Riley283, Dan Rujescu168,170, Pak C. Sham134,135,202, Pamela Sklar169,177,250, David St Clair294, Daniel R. Weinberger263,295, Jens R. Wendland251, Thomas Verge110,176,296, Mark J. Daly94, Patrick F. Sullivan119,142,245, Michael C. O’Donovan99,100

94Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts, USA. 95Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. 96Medical and Population Genetics Program, Broad Institute of MIT and Harvard,
